Sagimet Biosciences Inc. (SGMT) — SEC Financial Statements & Analysis

Sagimet Biosciences Inc. (SGMT) is a pharmaceutical preparations company, incorporated in DE. Sagimet Biosciences Inc. trades on Nasdaq as: SGMT. Sagimet Biosciences Inc. (SGMT)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Sagimet Biosciences Inc. carries a market cap of $410.58M, a P/E ratio of -8.72x, a P/B ratio of 1.60x, a P/S ratio of 44.52x, an enterprise value of $244.68M, and an EV/EBITDA multiple of -4.65x. On profitability, it posts an operating margin of -2624.50%, a net margin of -2205.20%, a Return on Equity (ROE) of -24.37%, a Return on Assets (ROA) of -23.49%, and a Return on Invested Capital (ROIC) of -59.10%. Per share, it reports EPS of $-0.89, diluted EPS of $-0.89, free cash flow per share of $-0.79, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -20.72% year-over-year, and EPS growth of -51.94% year-over-year. On the balance sheet, it maintains a current ratio of 45.02x, a quick ratio of 44.31x, working capital of $238.57M, a debt-to-equity ratio of 0.03x, a debt ratio of 0.03, free cash flow of $-41.72M (TTM), and net debt of $-165.90M. Figures sourced from SEC EDGAR.

Market Cap

$410.58M

P/E TTM

-8.72x

EPS TTM

$-0.89

P/B TTM

1.60x

ROE TTM

-24.37%

ROA TTM

-23.49%

Debt To Equity

0.03x

Free Cash Flow TTM

$-41.72M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR